Nasdaq · CIK 0001737927
CGC Canopy Growth Corp
F
10 / 100
Material weaknesses
2
Restatements
2
Auditor changes
0
Late filings
0
Quarters with open weakness
1
Remediations
0
Deductions
90
Remediation credit
0
Trailing 24 months from 2024-11-07. Rubric v1. How this is scored.
Disclosures, in the company's words
“accounting and legal costs arising from the March 31, 2026 restatement of our consolidated financial statements in connection with our warrant derivative liability of $0.5 million”
“approximately $0.4 million of continued legal costs arising from the restatement of our consolidated financial statements in connection with the review of the financial reporting matters related to the BioSteel business unit for the Prior Periods”
“approximately $0.5 million of accounting and legal costs arising from the March 31, 2026 restatement of our consolidated financial statements in connection with our warrant derivative liability”
“continued costs arising from the restatement of our consolidated financial statements in connection with the review of the financial reporting matters related to the BioSteel business unit for the Prior Periods of $0.2 million”
“approximately $0.2 million of continued legal costs arising from the restatement of our consolidated financial statements in connection with the review of the financial reporting matters related to the BioSteel business unit for the following previously filed periods”
“the risk that our March 31, 2026 restatement of our consolidated financial statements could negatively affect investor confidence and raise reputation risks”
“risks related to our ability to remediate the material weakness identified in our internal control over financial reporting, or inability to otherwise maintain an effective system of internal control”
“our remediation plan and our ability to remediate the material weakness in our internal control over financial reporting”
“continued costs arising from the restatement of our consolidated financial statements in connection with the review of the financial reporting matters related to the BioSteel business unit for the Prior Periods of $0.2 million”
“the risk that our March 31, 2026 restatement of our consolidated financial statements could negatively affect investor confidence and raise reputation risks”
“risks related to our ability to remediate the material weakness identified in our internal control over financial reporting, or inability to otherwise maintain an effective system of internal control”
“our remediation plan and our ability to remediate the material weakness in our internal control over financial reporting”
Filings read
- 10-Q · 2026-11-06read
- 8-K · 2026-11-06read
- 8-K · 2026-08-07queued
- 8-K · 2026-08-07queued
- 10-Q · 2026-08-07queued
- 10-K · 2026-06-15queued
- 8-K · 2026-06-15queued
- 8-K · 2026-05-15queued
- 8-K · 2026-01-08queued
- 8-K · 2025-08-29queued
- 10-K · 2025-05-30queued
- 8-K · 2025-02-28queued
Think something here is wrong? Request a correction. Open corrections hide the affected disclosure until resolved.